ADB-FUBHQUCA
Synthetic cannabinoid
| ADB-FUBHQUCA | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
ADB-FUBHQUCA is a synthetic cannabinoid that has been used in scientific research and is a designer drug. It is a potent agonist of the cannabinoid receptors, which are part of the endocannabinoid system.
Chemical structure
ADB-FUBHQUCA belongs to the indazole-3-carboxamide family of synthetic cannabinoids. Its chemical structure includes a 1-(4-fluorobenzyl) group attached to an indazole core, with an amide linkage to a tert-leucine moiety. The presence of the fluorobenzyl group is a common feature in many synthetic cannabinoids, contributing to their high affinity for cannabinoid receptors.
Pharmacology
As a synthetic cannabinoid, ADB-FUBHQUCA acts as a full agonist at the CB1 and CB2 receptors. These receptors are part of the G protein-coupled receptor family and are primarily involved in the modulation of neurotransmitter release in the central nervous system. The activation of these receptors by ADB-FUBHQUCA can lead to effects similar to those of tetrahydrocannabinol (THC), the active component of cannabis.
Legal status
The legal status of ADB-FUBHQUCA varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of medical use. It is often included in legislation targeting synthetic cannabinoids and other designer drugs.
Health effects
The use of ADB-FUBHQUCA, like other synthetic cannabinoids, can lead to a range of adverse health effects. These may include tachycardia, hypertension, nausea, vomiting, anxiety, and hallucinations. In severe cases, it can lead to seizures, psychosis, and renal failure.
Synthesis
The synthesis of ADB-FUBHQUCA involves the reaction of 1-(4-fluorobenzyl)-1H-indazole-3-carboxylic acid with tert-leucine and subsequent conversion to the amide. This process requires careful control of reaction conditions to ensure the purity and yield of the final product.
Related pages
Ad. Transform your life with W8MD's
GLP-1 weight loss injections special from $29.99


W8MD Medical Weight Loss, Sleep and Medspa offers physician-supervised medical weight loss programs: NYC medical weight loss Philadelphia medical weight loss
Affordable GLP-1 Weight Loss ShotsAffordable GLP-1 Weight Loss Shots
Budget GLP-1 injections NYC (insurance & self-pay options) Popular treatments:
- Semaglutide starting from $29.99/week
- Tirzepatide starting from $45.00/week
✔ Most insurances accepted for visits ✔ Prior authorization support when eligible
Start your physician weight loss NYC journey today:
📍 NYC: Brooklyn weight loss center 📍 Philadelphia: Philadelphia weight loss center
📞 Call: 718-946-5500 (NYC) | 215-676-2334 (Philadelphia)
Tags: Affordable GLP1 weight loss NYC, Wegovy NYC, Zepbound NYC, Philadelphia medical weight loss
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian